US ban on some Apple Watch sales now in effect
A US import ban has halted sales of certain Apple Watch models over alleged infringement of Masimo’s pulse oximetry patents, highlighting how aggressive patent enforcement can reshape consumer tech markets. Commenters debate whether Apple knowingly “sherlocked” Masimo’s technology after talks and employee poaching, how narrowly the underlying medical-device patents are defined, and why other wearables aren’t affected. The case reignites broader criticism of the patent and trade-commission system, with some calling it necessary protection for costly medical R&D and others seeing it as a broken regime that stifles competition and innovation.
Legal Context and Process
- Ban stems from a US International Trade Commission (ITC) ruling that certain Apple Watches infringe Masimo pulse oximetry patents.
- The ITC can block imports, not domestic manufacturing; appeals go to the Federal Circuit and potentially the Supreme Court, and the President can override but did not.
- This process is faster and more leverage-heavy than a normal district court patent case, which is why complainants use it.
Masimo vs Apple: Conduct and Strategy
- Many see this as “karma” given Apple’s past use of import bans (e.g., against HTC).
- Allegations: Apple met with Masimo about collaboration/licensing, then walked away and hired key Masimo staff, later shipping a similar feature.
- Some argue Apple is deliberately hard to settle with to avoid becoming an easy licensing target; others note Masimo claims Apple never meaningfully engaged after early talks.
- There’s debate whether Apple’s hiring of experts indicates the patents are non‑obvious, or simply that Apple wanted experienced people regardless.
Patent Scope and Technical Details
- Patents cover wrist‑worn, reflectance pulse oximetry: multi‑LED emitter arrays, a flat detector, on‑device processing, and specific mechanical features (opaque protrusion, chamfered edges to block light piping).
- Several commenters stress these are not the old “clip‑on” transmission oximeters; those use different physics and expired patents.
- Some think the independent claims are extremely broad (e.g., any processing by “one or more processors”), and expect a later court to possibly invalidate or narrow them; others note the ITC already found them valid.
Impact on Apple, Market, and Consumers
- Only models with the SpO2 sensor are affected; SE and existing imported inventory can still sell.
- Speculation: Apple may license the tech, redesign hardware (e.g., fewer LEDs or different geometry), remove the feature, or wait for appeals.
- Some see the feature as marginal/“wellness” marketing, others say they actively rely on the data.
Broader Patent and IP Debate
- Thread splits between:
- Support for enforcing patents even against Apple (“live by the patent, die by the patent”).
- Claims the system is broken, enabling blocking of long‑understood technology and incentivizing legal games over innovation.
- Broader arguments surface around patent duration, concept vs method patents, medical‑device development costs, and whether strong IP helps or harms smaller innovators facing large firms.